Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. RU-0211 EXCLUSIVE MANUFACTURING AND SUPPLY AGREEMENTExclusive Manufacturing and Supply Agreement • October 25th, 2006 • Sucampo Pharmaceuticals, Inc. • Pharmaceutical preparations
This RU-0211 EXCLUSIVE MANUFACTURING AND SUPPLY AGREEMENT (“Agreement”) is made this 24th day of June 2005 (the “Effective Date”), by and among Sucampo Pharma Europe Ltd., a corporation organized and existing under the laws of United Kingdom and having its principal office at 78 Cannon Street, London EC4N6NQ, United Kingdom (“SPE”), and R-Tech Ueno Ltd., a corporation organized and existing under the laws of Japan and having its principal office at 1-1-7 Uchisaiwai-cyo, Chiyoda-ku, Tokyo 100-0011, Japan (“RTU”) (each referred to herein as a “Party” and collectively as the “Parties”).
Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. RU-0211 EXCLUSIVE MANUFACTURING AND SUPPLY AGREEMENTExclusive Manufacturing and Supply Agreement • October 25th, 2006 • Sucampo Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
THIS RU-0211 EXCLUSIVE MANUFACTURING AND SUPPLY AGREEMENT (“Agreement”) is made this 23rd day of June 2004 (the “Effective Date”), by and among Sucampo Pharmaceuticals, Inc., a corporation organized and existing under the laws of the state of Delaware, U.S.A. and having its principal office at 4733 Bethesda Avenue, Suite 450, Bethesda, Maryland 20814, U.S.A. (“SPI”), and the Pharma Chemical division (formally Sucampo Pharma Manufacturing Division) (“PCD”) of R-Tech Ueno, Ltd., a corporation organized and existing under the laws of Japan and having its registered office at 4-1, Techno Park, Sanda, Hyogo, Japan 669-1339 (“RTU”) (each referred to herein as a “Party” and collectively as the “Parties”).
SPI-8811 AND SPI-017 EXCLUSIVE CLINICAL MANUFACTURING AND SUPPLY AGREEMENTExclusive Clinical Manufacturing and Supply Agreement • October 25th, 2006 • Sucampo Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
THIS SPI-8811 AND SPI-017 EXCLUSIVE CLINICAL MANUFACTURING AND SUPPLY AGREEMENT (“Agreement”) is made as of this 4th day of October 2006 (the “Signing Date”), by and among Sucampo Pharmaceuticals, Inc., a corporation organized and existing under the laws of the state of Delaware, U.S.A. and having its principal office at 4733 Bethesda Avenue, Suite 450, Bethesda, Maryland 20814, U.S.A. (“SPI”), and R-Tech Ueno, Ltd., a corporation organized and existing under the laws of Japan and having its registered office at 10F, Yamato Life Insurance Bldg., 1-1-7 Uchisaiwaicho, Chiyoda-ku, Tokyo, Japan 100-0011 (“RTU”) (each referred to herein as a “Party” and collectively as the “Parties”).
